Next Article in Journal
Adipokines, Metabolic Hormones and Their Associations with Abdominal Obesity against a Background of Hyper-LDL-C in Young People
Next Article in Special Issue
Predicting Intention to Participate in Community Physical Activities for Adults with Physical Disabilities
Previous Article in Journal
Personalized Medicine in Otolaryngology: Special Topic Otology
Previous Article in Special Issue
Prevalence of Dental Anomalies in Taiwanese Children with Cleft Lip and Cleft Palate
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Outcomes of COVID-19 Patients with Spontaneous Intracerebral Hemorrhage Comorbidity and the Efficacy of Enoxaparin in Decreasing the Mortality Rate in Them: Single Egyptian Center Report

1
Neurosurgery Department, Faculty of Medicine, Beni-Suef University, Beni-Suef 62521, Egypt
2
Department of Clinical Pharmacy, Teaching Hospitals of Faculty of Medicine, Faculty of Medicine, Beni-Suef University, Beni-Suef 62521, Egypt
3
Department of Clinical Pharmacy, Faculty of Pharmacy, Nahda University (NUB), Beni-Suef 62764, Egypt
4
Tropical Medicine and Infectious Diseases Department, Faculty of Medicine, Beni-Suef University, Beni-Suef 62521, Egypt
5
Public Health and Community Medicine Department, Faculty of Medicine, Beni-Suef University, Beni-Suef 62521, Egypt
6
Department of Microbiology and Immunology, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62521, Egypt
7
Internal Medicine Department, Faculty of Medicine, Beni-Suef University, Beni-Suef 62521, Egypt
8
Clinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62521, Egypt
*
Authors to whom correspondence should be addressed.
J. Pers. Med. 2022, 12(11), 1822; https://doi.org/10.3390/jpm12111822
Submission received: 9 September 2022 / Revised: 24 October 2022 / Accepted: 27 October 2022 / Published: 2 November 2022
(This article belongs to the Special Issue Epidemiology: An Important Science of Public Health and Disease)

Abstract

:
Patients with neurological comorbidities are more likely to develop severe COVID-19. We aimed to detect the outcomes of COVID-19 patients with spontaneous intracerebral hemorrhage comorbidity and the role of enoxaparin in decreasing the mortality rate in these cases, even though enoxaparin is a potential cause of intracerebral hemorrhage. The patients were checked on to detect surveillance outcomes, the relationship between mortality and patient characteristics, and the relationship between enoxaparin and study outcomes. Chest condition and GCS improved in 67.9% of participants. Hematoma course increased in 49.1%. Midline-shift, brain-edema, and COVID symptoms improved in 67.9%. There was a non-significant difference in mortality regarding age and gender. There was a significant difference in mortality regarding treatment with enoxaparin; 75% of the patients who did not receive enoxaparin died. 92.6% of the patients who showed decreases in hematoma course were administered enoxaparin. 76.9% of the patients who showed increases in hematoma-course were administered enoxaparin. Most of the patients who were admitted to the neurosurgical unit with spontaneous intracerebral hemorrhage acquired the COVID-19 infection. Most of the cases included in this study did not progress to severe cases. The dying patients showed deterioration in both neurological and COVID-19 symptoms. The anticoagulant properties of enoxaparin given earlier before and throughout the infection can considerably reduce mortality in COVID-19 individuals with spontaneous intracerebral hemorrhage. It is recommended to use enoxaparin for cases with spontaneous intracerebral hemorrhage and COVID-19 regardless of hematoma size because the rate of improvement was greater than the mortality rate after using enoxaparin in this study.

1. Introduction

Coronavirus infection is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. It often appears as respiratory tract symptoms and fever [2,3,4,5]. To evaluate the patients with COVID-19 infection, the Dutch Radiological Society developed a score system based on chest CT and patient data in March 2020; the COVID-19 Reporting and Data System (CO-RADS) included clinical findings and laboratory test results, as well as CT records. The level of suspicion ranged from very low to very high (CO-RADS categories 1–5), with category 0 indicating no infection and category 6 indicating RT-PCR-positive SARS-CoV-2 infection at the time of examination. [1]. In clinical settings, coronavirus may cause severe symptoms, particularly in elderly patients with many comorbidities [6]. The risk factors (comorbidities) for severe coronavirus symptoms include cerebrovascular disease, diabetes mellitus, cardiovascular disease, hypertension, and intracerebral hemorrhage (ICH) [7]. A growing number of studies on coronavirus have reported many neurological complications, such as Guillain–Barré syndrome [8]., acute stroke, hyposmia, and encephalitis [9,10]. It has been demonstrated that approximately 30% of coronavirus patients develop neurological complications, which are frequently linked to a more severe infection, implying that coronavirus neurotropism is a possible mechanism of neurological damage [11,12]. ICH is indeed a very rare but well-documented COVID-19 complication [13]. Therefore, ICH can be regarded as a risk factor (comorbidity) and a complication of severe coronavirus infection. Many research studies looked at the ICH as a COVID-19 complication, but few published studies look at the ICH as a pre-existing comorbidity for severe coronavirus infection. Accordingly, we decided to conduct an observational study to detect the outcomes of COVID-19 patients with pre-existing spontaneous ICH (comorbidity). Primary ICH can happen in the presence or absence of known risk factors such as arterial hypertension (HTN) or anticoagulation therapy (such as enoxaparin) as a COVID-19 thrombo-prophylaxis [14,15,16]. A prior study found that moderate-to-severe coronavirus patients benefit from anticoagulant therapy, such as enoxaparin, in terms of lowering mortality in this disease [17,18,19]. Then, we decided to detect the role of enoxaparin in decreasing the mortality rate in COVID-19 patients with pre-existing spontaneous ICH, even though it is a potential cause for worsening ICH.
Therefore, the objective of this study was to detect the outcomes of COVID-19 patients with pre-existing spontaneous intracerebral hemorrhage (comorbidity) and to detect the role of enoxaparin in decreasing the mortality rate in these cases, although it is a potential cause for worsening intracerebral hemorrhage.

2. Materials and Methods

2.1. The Study Design

A cohort study was conducted from May 2021 to December 2021, including 102 patients who were admitted to the neurosurgical unit with spontaneous ICH. The study protocol was approved by the Research Ethical Committee of Beni-Suef University (REC-H-PhBSU-20010, date of approval: March 2021) and was carried out at Beni-Suef University Hospital following the Helsinki Declaration. The patient’s family provided written informed consent. Of the total patients, 53 patients were infected with SARS-CoV-2, and they were laboratory-confirmed as having SARS-CoV-2 infection using reverse transcription-polymerase chain reaction (RT-PCR). The patients were treated for COVID-19 according to the guidelines of the World Health Organization (WHO) and the Egyptian protocol.
Through repeated negative RT-PCR tests performed within 45 days of the initial positive test, SARS-CoV-2 clearance was determined in all surviving patients.

2.1.1. Inclusion Criteria

  • Patients were more than 18-years-old.
  • Patients were admitted to the hospital for spontaneous intracerebral hemorrhage and acquired COVID-19 infection during the period of their hospital admission.
  • Positive cases of COVID-19 by RT-PCR test.

2.1.2. Exclusion Criteria

  • Severe hepatic disease patients.
  • Patients who were pregnant or lactating.
  • Patients aged less than 18-years-old.

2.2. Sampling Techniques

The data collected from patients who had pre-existing spontaneous intracerebral hemorrhage comorbidities after confirmation of their infection with COVID-19 were analyzed.

2.3. Data Collection

From the patients, the following was collected:
  • The participants’ characteristics and disease characteristics of COVID-19 disease symptoms and computed tomography (CT) scan.
  • The neurological symptoms and CT brain findings on admission.
  • Management of the studied patients regarding their COVID-19 disease and neurosurgical management.
  • The outcomes of the patients who were studied.
  • The association between mortality and various patient characteristics.
  • The relation between enoxaparin and the outcome of the study.
Neurological parameters were collected for follow-up and monitoring of the patients to detect the link between patients’ neurological comorbidities and disease severity (recovery time) and clinical prognosis.

2.4. Statistical Analysis

The data were analyzed using IBM SPSS advanced statistics version 22 (SPSS Inc., Chicago, IL, USA), and the numerical data are expressed as mean and standard deviation or median and range, as appropriate. The qualitative data are expressed as frequency and percentage. The comparison between subgroups was performed using an independent t-test regarding scale variables, while the comparison regarding categorical variables was done using chi-squared or Fisher exact tests. A p-value < 0.05 was considered statistically significant.

3. Results

3.1. Participants’ Characteristics and COVID-19 Disease Characteristics (Symptoms and CT)

A total of 53 patients (30 males) completed the study. Their age (mean ± SD) was (59.1 ± 14.2). Regarding oxygen therapy, 60.4% of the patients required ordinary oxygen therapy, 18.9% required high-flow nasal oxygen therapy, and 20.8% required mechanical ventilation.
The characteristics of the studied patients and the disease characteristics of COVID-19 (symptoms and CT) are shown in Table 1.

3.2. The Neurological Symptoms and CT Brain Findings on Admission

The mean Glasgow Coma Scale (GCS) for the patients was 11.5. Of all the patients (regarding the conscious patients), 1.9% suffered from diminished vision, 5.7% suffered from headache, 35.8% had left-side weakness and 26.4% had a right-side weakness. Regarding the CT brain findings, 28.3% of the patients had midline shift and brain edema, 5.7% had bilateral basal ganglia hematoma, 7.5% had left basal ganglia hematoma, and 5.7% had right basal ganglia hematoma. 9.4% had bilateral thalamic hematoma, 5.7% had left thalamic hematoma, and 26.4% had a right thalamic hematoma. 3.8% had bilateral temporo-parietal hematoma, 9.4% had left temporo-parietal hematoma, and 1.9% had right temporo-parietal hematoma. 1.9% had a bilateral frontal hematoma and 1.9% had a right frontal hematoma. 24.6% had intraventricular hemorrhage (IVH), 3.8% had a pontine hemorrhage, and 5.7% had hydrocephalus. The mean hematoma size ± SD was 14.9 ± 11.9. The hematoma course on admission was stationary in 28.3% of the participants, regressive in 22.6%, and progressive in 49.1% of them. The neurological symptoms and CT brain findings are shown in Table 2.

3.3. Management of the Studied Patients regarding Their COVID-19 Disease and Neurosurgical Management

Of all the study patients, 32.1% received a prophylactic dose of enoxaparin on day 3, 52.8% received a prophylactic dose on day 3, followed by a therapeutic dose on day 7, and 15.1% did not receive enoxaparin. Regarding the neurosurgical management, 9.4% of the patients were evacuated, and 5.7% underwent ventriculo-subglia drain (VSD) surgery. Management of the studied patients regarding their COVID-19 disease and neurosurgical management is shown in Table 3.

3.4. The Outcomes of the Studied Patients

The condition of the chest and GCS had improved in 67.9% of the participants by the end of the study. The hematoma course increased in 49.1% of the patients. The midline shift, brain edema, and COVID symptoms improved in 67.9% of the participants. The outcomes of the patients who were studied are shown in Table 4.

3.5. The Relation between Mortality and Different Patients’ Characteristics

There was no significant difference in mortality between patients depending on gender and age. However, there was a significant difference in mortality among patients depending on chest condition, COVID-19 symptoms, GCS, midline shift, and brain edema (p-value < 0.001). There was a significant difference in mortality among patients with temporo-parietal hematoma (p-value = 0.047). There was a significant difference in mortality among patients depending on hematoma size (p-value < 0.001). The hematoma sizes (mean ± SD) were (4.612 ± 567) and (13.00 ± 3.202) for the living and dead patients, respectively. There was a significant difference in the mortality among patients depending on the treatment with enoxaparin, where 75% of the patients who did not receive enoxaparin died, while in patients who were administered enoxaparin, it was 24.4% (p-value = 0.026). The ICU stay duration (mean ± SD) was (12.28 ± 7.7) and (7.29 ± 5.193) for the living and dead patients, respectively (p-value = 0.019). The relationship between mortality and different patients’ characteristics is shown in Table 5.

3.6. The Relationship between Enoxaparin and the Outcome of the Study

Of all the patients who were treated with enoxaparin, 94.4% showed significant improvement in their chest condition, the mean Glasgow Coma Scale (GCS), the midline shift, brain edema, and COVID-19 symptoms (p-value = 0.01). An amount of 55.6% of the patients who were administered enoxaparin showed decreases in hematoma course and 25% who did not receive enoxaparin. Enoxaparin was given to 94.4% of the patients who were still alive. The relationship between enoxaparin and the study outcome is shown in Table 6.

4. Discussion

The findings of this study imply that coronavirus may worsen neurological disorders and, subsequently, mortality in people who have a pre-existing spontaneous intracerebral hemorrhage. This was also reported in previous studies [7,20,21].
According to a recent retrospective study, inpatients in a neurological unit who were infected with COVID-19 had a worse prognosis, developed severe cases, and experienced poorer outcomes than those who were not infected [13].
This is the first Egyptian study that shows how COVID-19 can make neurological symptoms worse in people who already have pre-existing spontaneous intracerebral hemorrhage and how many people die from it.
In particular, approximately 32% of patients with pre-existing spontaneous intracerebral hemorrhage died after being infected with COVID-19 [22]. The patients who died had deteriorating neurological symptoms such as decreased GCS, increased hematoma course, med line shift, and brain edema, whereas COVID-19 infection causes the production of the central nervous system and systemic cytokines, prostaglandins, and monokines, which cause patients with neurological disorders to experience an abrupt decrease in cognition and a worsening prognosis [7,23,24].
In this study, about 53% of the dead patients required mechanical ventilation, indicating poor clinical outcomes with an elevated occurrence of severe conditions which led to mortality [25]. Worsening chest conditions were reported in all the dead patients.
In this study, the majority of hematoma patients had severe coronavirus. This could be because these people have risk factors for severe coronaviruses, such as age, hypertension, and diabetes. These risk factors also increase the mortality rate [26].
The majority of the dead patients in this study showed an increased size of hemorrhage and edema with midline shift, which caused compression on the brain stem and development of the hematoma course into a state of being progressive, leading to death. This may explain why most of the patients with progressive hematoma courses in this study died. These findings were confirmed by the study of TM Tu et al. [27].
For patients with increased hematoma course (hematoma size greater than 30 ml), the patients underwent surgery to evacuate the hematoma if the GCS score was between 7 and 13 and if the chest condition did not develop into severe pneumonia [28]. Of all the participants in this study, five of them underwent evacuation of the hematoma.
Ventricular subglia drain (VSD) is surgery to drain excess CSF from the ventricles (hydrocephalus) into the subglia space to relieve tension regardless of the score of GCS and the chest condition [29]. Three patients in this study suffered from hydrocephalus and urgently underwent VSD surgery.
For patients with a GCS score of less than 7 or whose chest condition has developed to a severe degree, dehydration therapy is used to monitor the cerebral edema and decrease the intracranial hemorrhage until their condition allows them to undergo surgery [30]. Mannitol, albumin, and glycerin fructose are the most commonly used osmotherapy medicines. Mannitol is the most commonly used dehydrant [31]. In this study, furosemide and mannitol were used as dehydration therapies. This combination results in a greater decrease in the amount of water in the brain than mannitol alone did. Furosemide enhances the effect of mannitol on plasma osmolality, causing a greater decrease in brain water content [32].
Difficulties with spontaneous breathing and respiratory secretion cleaning may exacerbate pneumonia in patients with pre-existing spontaneous intracerebral hemorrhage [33,34]. About 32.1% of the patients used a prophylactic dose (20 mg/0.4 ml twice daily) of enoxaparin on day 3 of their symptoms, and 52.8% used a prophylactic dose on day 3, followed by a therapeutic dose (60 mg/0.4 ml twice daily) on day 7. Anticoagulant use should be continued for four weeks for antithrombotic prophylaxis [35,36]. Approximately two-thirds of the cases included in this study did not progress to severe, which is especially intriguing given their previously severe and debilitating clinical profile. This unexpected outcome could be explained by the fact that these patients were given an anticoagulant for the prevention of thromboembolism, which is a result of commonly suffering from immobility for an extended duration. In reality, because of their severe neurological dysfunction, the majority of the patients in our study were bedridden, and anticoagulant medication was initiated early in their hospitalization, before SARS-CoV-2 infection. Early anticoagulant therapy with enoxaparin has been proposed as a helpful treatment since it has been linked to lower mortality in severe instances [37,38]. The anticoagulant effects could be explained through two-pronged mechanisms: anticoagulant, which minimizes the disease’s damaging effect, and anti-inflammatory, which prevents severe SARS-CoV-2 infection manifestations. The discovery that anticoagulants decrease cytokine release in a variety of inflammatory situations lends support to our interpretation [39]. Several studies have also found that enoxaparin improves coagulation issues in coronavirus patients and has anti-inflammatory properties that lower IL-6 and increase lymphocyte percentage. Enoxaparin appears to be useful in the treatment of coronavirus [40,41]. Furthermore, the antiviral activity of several anticoagulants, such as enoxaparin, has been predicted and supported by recent research [40,41]. However, the risk of bleeding problems from anticoagulant drugs in people with SARS-CoV-2 should not be ignored [41].
In terms of oxygen therapy, 60.4% of the patients in this study received standard oxygen therapy, 18.9% required high-flow nasal oxygen therapy, and 20.8% required mechanical ventilation. This shows that these patients developed moderate-to-severe chest conditions and required ICU care. Regarding the CT chest findings, 50.9% of the patients in this study were CORAD 3, 30.2% were CORAD 4, and 18.9% were CORAD 5. This means that people who have a pre-existing spontaneous intracerebral hemorrhage can quickly go from mild to severe COVID-19, which can lead to death.
In this study, there was no statistically significant difference in mortality among patients based on gender or age. However, there was a statistically significant difference in mortality among patients based on the comorbid pre-existing spontaneous intracerebral hemorrhage such as GCS, midline shift, brain edema, and hematoma course.
The hematoma sizes (mean ± SD) were (4.612 ± 2.567) and (13.00 ± 3.202) for the living and dead patients, respectively. The rising mortality rate could be explained by a hyperimmune response caused by cytokine storms, or by a direct viral invasion of human brain cells via transcribrial, hematogenous, and neural retrograde dissemination routes [42]. Furthermore, angiotensin-converting enzyme 2 (ACE2) receptors produced by capillary endothelial cells in the brain may be involved in SARS-CoV-2-induced neurological problems. Endothelial rupture in the brain causes irreparable brain injury, contributing to SARS-CoV-2 neurologic symptoms pathophysiology [42]. Moreover, higher D dimer and CRP levels caused by a state of high inflammation and activation of the coagulation cascade may result in cerebrovascular problems in coronavirus patients. As a result, the potential processes could include a combination of immunological, vascular, and neural variables. A neurologic manifestation of COVID-19 may occur in addition to preexisting intracerebral hemorrhage. A prior study found a link between COVID-19 and neurological illnesses, with more than 30% of hospitalized coronavirus patients developing neurological disorders [43]., ranging from mild to life-threatening in severity. As a result, it needs to be included in any individual’s differential diagnosis presenting with increasing neurological symptoms, particularly within the current epidemic. As a result, individuals with severe coronavirus infection, as well as previous neurological diseases, should be treated with special caution because they are more likely to die [44].
There was also a statistically significant difference in mortality between patients based on their treatment with enoxaparin (p-value = 0.026), where 75% of the patients who did not receive enoxaparin died. A recent study confirmed this finding, reporting that enoxaparin reduces mortality in coronavirus patients with moderate to severe cases [17]. Most patients (92.6%) who showed a decrease in hematoma course were administered enoxaparin. On the other hand, 76.9% of the patients who showed an increase in hematoma course were administered enoxaparin. As a result, we recommend using enoxaparin for patients with spontaneous intracranial hemorrhage and COVID-19 regardless of hematoma course because the rate of improvement was greater than the mortality rate after using enoxaparin in this study.
The increase in hematoma course in the patients who were administered enoxaparin, which caused their deaths, may have been due to large hematoma size and deterioration in GCS, as well as chest condition, which was also reported in previous studies [45,46]. Regarding the chest condition, oxygen saturation decreased in the blood, which led to anorexia and deteriorated consciousness and GCS. In patients with preexisting spontaneous intracerebral hemorrhage and COVID-19 infection, a lower GCS can be considered a predictor of poor outcomes [47,48].

5. Conclusions

Our findings suggest that more than half of the patients who were admitted to the neurosurgical unit with spontaneous intracerebral hemorrhage acquired COVID-19 infection during their hospitalization period. Nearly two-thirds of the cases included in this study did not progress to severe cases. A third of the study patients died as a result of deteriorating neurological and COVID-19 symptoms such as decreased GCS, increased hematoma course, med line shift, brain edema, and chest condition. The antithrombotic efficacy of enoxaparin given earlier, both before and throughout the COVID-19 infection, can considerably reduce mortality in COVID-19 individuals with pre-existing spontaneous intracerebral hemorrhage. It is recommended to use enoxaparin for patients with preexisting spontaneous intracerebral hemorrhage and COVID-19 regardless of hematoma size because, in this study, the rate of improvement was greater than the mortality rate after using enoxaparin.

Author Contributions

Conceptualization, M.S.; methodology, formal analysis, investigation, resources, data curation, writing—original draft preparation, writing—review and editing, M.S., M.O.E., A.M.F., D.M.K., A.O.E.-G., T.M.M. and M.E.A.A.; visualization, M.S.; supervision, M.S.; project administration, M.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Research Ethical Committee of Beni-Suef University (REC-H-PhBSU-20010, date of approval: March 2021).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

Data is available upon request.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Elgendy, M.O.; Khalaf, A.M.; El-Gendy, O.; Abdelrahman, M.A.; El Gendy, S.O.; Hamied, A.M.A.; Essam, O.; Al Amir, K.; Yousry, E.M.; Abdelrahim, M.E. An Observational Study on the Management of COVID-19 Patients in Limited-Resource Hospitals. J. Clin. Nurs. Res. 2022, 6, 43–53. [Google Scholar] [CrossRef]
  2. Klok, F.A.; Kruip, M.J.H.A.; van der Meer, N.J.M.; Arbous, M.S.; Gommers, D.A.M.P.J.; Kant, K.M.; Kaptein, F.H.J.; van Paassen, J.; Stals, M.A.M.; Huisman, M.V.; et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res. 2020, 191, 145–147. [Google Scholar] [CrossRef] [PubMed]
  3. Benger, M.; Williams, O.; Siddiqui, J.; Sztriha, L. Intracerebral haemorrhage and COVID-19: Clinical characteristics from a case series. Brain Behav. Immun. 2020, 88, 940–944. [Google Scholar] [CrossRef] [PubMed]
  4. Elgendy, M.O.; Elmawla, M.N.A.; Hamied, A.M.A.; El Gendy, S.O.; Abdelrahim, M.E.A. COVID-19 patients and contacted person awareness about home quarantine instructions. Int. J. Clin. Practic. 2020, 75, e13810. [Google Scholar] [CrossRef] [PubMed]
  5. Elgendy, M.O.; El-Gendy, A.O.; Abdelrahim, M.E. Public awareness in Egypt about COVID-19 spread in the early phase of the pandemic. Patient Educ. Couns. 2020, 103, 2598–2601. [Google Scholar] [CrossRef]
  6. Panciani, P.P.; Saraceno, G.; Zanin, L.; Renisi, G.; Signorini, L.; Fontanella, M.M. Letter: COVID-19 Infection Affects Surgical Outcome of Chronic Subdural Hematoma. Neurosurgery 2020, 87, E167–E171. [Google Scholar] [CrossRef]
  7. Kubota, T. and N. Kuroda, Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological disorders and COVID-19: A systematic review. Clin. Neurol. Neurosurg. 2021, 200, 106349. [Google Scholar] [CrossRef]
  8. Bigaut, K.; Mallaret, M.; Baloglu, S.; Nemoz, B.; Morand, P.; Baicry, F.; Godon, A.; Voulleminot, P.; Kremer, L.; Chanson, J.-B.; et al. Guillain-Barré syndrome related to SARS-CoV-2 infection. Neurol. Neuroimmunol. Neuroinflamm. 2020, 7, e785. [Google Scholar] [CrossRef]
  9. Ellul, M.A.; Benjamin, L.; Singh, B.; Lant, S.; Michael, B.D.; Easton, A.; Kneen, R.; Defres, S.; Sejvar, J.; Solomon, T. Neurological associations of COVID-19. Lancet Neurol. 2020, 19, 767–783. [Google Scholar] [CrossRef]
  10. Elgendy, M.; Tayel, S.; Abdelrahim, M.; Ali, A.; Meabed, M. Role of Piracetam in Treatment of Cerebral Palsy Disease. J. Behav. Health 2012, 1, 53–58. [Google Scholar] [CrossRef]
  11. Josephson, S.A.; Kamel, H. Neurology and COVID-19. JAMA 2020, 324, 1139–1140. [Google Scholar] [CrossRef]
  12. Elgendy, M.O.; El-Gendy, A.O.; Alzarea, A.I.; Mahmoud, S.; Alqahtani, S.S.; Fahmy, A.M.; El-Seedi, H.R.; Sayed, A.M.; Alatawi, A.D.; Abdelrahim, M.E.A.; et al. SARS-CoV-2 Post Vaccinated Adverse Effects and Efficacy in the Egyptian Population. Vaccines 2022, 10, 18. [Google Scholar] [CrossRef]
  13. Margos, N.P.; Meintanopoulos, A.S.; Filioglou, D.; Ellul, J. Intracerebral hemorrhage in COVID-19: A narrative review. J. Clin. Neurosci. 2021, 89, 271–278. [Google Scholar] [CrossRef]
  14. Herman, C.; Mayer, K.; Sarwal, A. Scoping review of prevalence of neurologic comorbidities in patients hospitalized for COVID-19. Neurology 2020, 95, 77–84. [Google Scholar] [CrossRef]
  15. Sayed, A.M.; Khalaf, A.M.; Abdelrahim, M.E.A.; Elgendy, M.O. Repurposing of some anti-infective drugs for COVID-19 treatment: A surveillance study supported by an in silico investigation. Int. J. Clin. Practic. 2020, 75, e13877. [Google Scholar] [CrossRef]
  16. Zawbaa, H.M.; Osama, H.; El-Gendy, A.; Saeed, H.; Harb, H.S.; Madney, Y.M.; Abdelrahman, M.; Mohsen, M.; Ali, A.M.A.; Nicola, M.; et al. Effect of mutation and vaccination on spread, severity, and mortality of COVID-19 disease. J. Med. Virol. 2021, 94, 197–204. [Google Scholar] [CrossRef]
  17. Billett, H.H.; Reyes-Gil, M.; Szymanski, J.; Ikemura, K.; Stahl, L.R.; Lo, Y.; Rahman, S.; Gonzalez-Lugo, J.D.; Kushnir, M.; Barouqa, M.; et al. Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality. Thromb. Haemost. 2020, 120, 1691–1699. [Google Scholar] [CrossRef]
  18. Elgendy, M.O.; Abdelrahim, M.E.A. Public awareness about coronavirus vaccine, vaccine acceptance, and hesitancy. J. Med. Virol. 2021, 93, 6535–6543. [Google Scholar] [CrossRef]
  19. Elgendy, M.O.; Abdelrahman, M.A.; Osama, H.; El-Gendy, A.O.; Abdelrahim, M.E.A. Role of repeating quarantine instructions and healthy practices on COVID-19 patients and contacted persons to raise their awareness and adherence to quarantine instructions. Int. J. Clin. Practic. 2021, 75, e14694. [Google Scholar] [CrossRef]
  20. Eid, R.A.; Elgendy, M.O.; El-Gendy, A.O.; Elgendy, S.O.; Belbahri, L.; Sayed, A.M.; Rateb, M.E. Efficacy of Ceftazidime and Cefepime in the Management of COVID-19 Patients: Single Center Report from Egypt. Antibiotics 2021, 10, 1278. [Google Scholar] [CrossRef]
  21. Elgendy, M.O.; El-Gendy, A.O.; Mahmoud, S.; Mohammed, T.Y.; Abdelrahim, M.E.A.; Sayed, A.M. Side Effects and Efficacy of COVID-19 Vaccines among the Egyptian Population. Vaccines 2022, 10, 109. [Google Scholar] [CrossRef] [PubMed]
  22. Battistoni, I.; Francioni, M.; Morici, N.; Rubboli, A.; Podda, G.M.; Pappalardo, A.; Abdelrahim, M.E.; Elgendy, M.O.; Khalaf, A.M.; Hamied, A.A.M.; et al. Pre- and in-hospital anticoagulation therapy in coronavirus disease 2019 patients: A propensity-matched analysis of in-hospital outcomes. J. Cardiovasc. Med. 2021, 23, 264–271. [Google Scholar] [CrossRef] [PubMed]
  23. Cunningham, C. Systemic inflammation and delirium: Important co-factors in the progression of dementia. Biochem. Soc. Trans. 2011, 39, 945–953. [Google Scholar] [CrossRef] [PubMed]
  24. Xu, J.; Zhong, S.; Liu, J.; Li, L.; Li, Y.; Wu, X.; Li, Z.; Deng, P.; Zhang, J.; Zhong, N.; et al. Detection of Severe Acute Respiratory Syndrome Coronavirus in the Brain: Potential Role of the Chemokine Mig in Pathogenesis. Clin. Infect. Dis. 2005, 41, 1089–1096. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Hazariwala, V.; Hadid, H.; Kirsch, D.; Big, C. Spontaneous pneumomediastinum, pneumopericardium, pneumothorax and subcutaneous emphysema in patients with COVID-19 pneumonia, a case report. J. Cardiothorac. Surg. 2020, 15, 301. [Google Scholar] [CrossRef]
  26. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020, 395, 1054–1062. [Google Scholar] [CrossRef]
  27. Tu, T.M.; Goh, C.; Tan, Y.K.; Leow, A.S.; Pang, Y.Z.; Chien, J.; Shafi, H.; Chan, B.P.; Hui, A.; Koh, J.; et al. Cerebral Venous Thrombosis in Patients with COVID-19 Infection: A Case Series and Systematic Review. J. Stroke Cerebrovasc. Dis. 2020, 29, 105379. [Google Scholar] [CrossRef]
  28. Balasa, A.; Ghiga, D.; Andone, R.-S.; Zahan, A.; Florian, I.; Chinezu, R. Effects of Surgery on the 30-Day Survival Rate in Spontaneous Supratentorial Intracerebral Hemorrhage. Brain Sci. 2020, 11, 5. [Google Scholar] [CrossRef]
  29. Verrees, M.; Selman, W.R. Management of normal pressure hydrocephalus. Am. Fam. Physician 2004, 70, 1071–1078. [Google Scholar]
  30. Wang, W.; Zhou, N.; Wang, C. Minimally Invasive Surgery for Patients with Hypertensive Intracerebral Hemorrhage with Large Hematoma Volume: A Retrospective Study. World Neurosurg. 2017, 105, 348–358. [Google Scholar] [CrossRef]
  31. Zheng, H.; Chen, C.; Zhang, J.; Chunli, C. Mechanism and Therapy of Brain Edema after Intracerebral Hemorrhage. Cerebrovasc. Dis. 2016, 42, 155–169. [Google Scholar] [CrossRef]
  32. Thenuwara, K.; Todd, M.M.; Brian, J.E. Effect of Mannitol and Furosemide on Plasma Osmolality and Brain Water. Anesthesiology 2002, 96, 416–421. [Google Scholar] [CrossRef]
  33. Alhazzani, W.; Møller, M.H.; Arabi, Y.M.; Loeb, M.; Gong, M.N.; Fan, E.; Dzierba, A. Surviving Sepsis Campaign: Guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020, 46, 854–887. [Google Scholar] [CrossRef] [Green Version]
  34. Richardson, S.; Hirsch, J.S.; Narasimhan, M.; Crawford, J.M.; McGinn, T.; Davidson, K.W.; The Northwell COVID-19 Research Consortium. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized with COVID-19 in the New York City Area. JAMA 2020, 323, 2052–2059. [Google Scholar] [CrossRef]
  35. Di Gennaro, F.; Marotta, C.; Storto, M.; D’Avanzo, C.; Foschini, N.; Maffei, L.; de Gaetano, G.; Centonze, D.; Iezzi, E. SARS-CoV-2 transmission and outcome in neuro-rehabilitation patients hospitalized at neuroscience hospital in Italy. Mediterr. J. Hematol. Infect. Dis. 2020, 12, e2020063. [Google Scholar] [CrossRef]
  36. Moein, S.T.; Hasheiman, S.M.R.; Mansourfashar, B.; Khorram-Tousi, A.; Tabarsi, P.; Doty, R.L. Smell dysfunction: A biomarker for COVID-19. Int. Forum Allergy Rhinol. 2020, 10, 944–950. [Google Scholar] [CrossRef] [Green Version]
  37. Tang, N.; Li, D.; Wang, X.; Sun, Z. Los parámetros anormales de coagulación están asociados con un pronóstico deficiente en pacientes con neumonía por coronavirus novedosa. J. Thromb. Haemost. 2020, 18, 844–847. [Google Scholar] [CrossRef] [Green Version]
  38. Zhang, Y.; Cao, W.; Xiao, M.; Li, Y.J.; Yang, Y.; Zhao, J.; Zhou, X.; Jiang, W.; Zhao, Y.Q.; Zhang, S.Y.; et al. Clinical and coagulation characteristics of 7 patients with critical COVID-19 pneumonia and acro-ischemia. Zhonghua Xue Ye Xue Za Zhi Zhonghua Xueyexue Zazhi 2020, 41, E006. [Google Scholar]
  39. Tang, N.; Bai, H.; Chen, X.; Gong, J.; Li, D.; Sun, Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J. Thromb. Haemost. 2020, 18, 1094–1099. [Google Scholar] [CrossRef] [Green Version]
  40. Tandon, R.; Sharp, J.S.; Zhang, F.; Pomin, V.H.; Ashpole, N.M.; Mitra, D.; Linhardt, R.J. Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives. bioRxiv 2020. preprint. [Google Scholar] [CrossRef]
  41. Mousavi, S.; Moradi, M.; Khorshidahmad, T.; Motamedi, M. Anti-Inflammatory Effects of Heparin and Its Derivatives: A Systematic Review. Adv. Pharmacol. Sci. 2015, 2015, 507151. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Baig, A.M.; Khaleeq, A.; Ali, U.; Syeda, H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host–Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chem. Neurosci. 2020, 11, 995–998. [Google Scholar] [CrossRef] [PubMed]
  43. Munhoz, R.P.; Pedroso, J.L.; Nascimento, F.A.; Almeida, S.M.D.; Barsottini, O.G.P.; Cardoso, F.E.C.; Teive, H.A.G. Neurological complications in patients with SARS-CoV-2 infection: A systematic review. Arq. Neuro-Psiquiatr. 2020, 78, 290–300. [Google Scholar] [CrossRef] [PubMed]
  44. Katal, S.; Balakrishnan, S.; Gholamrezanezhad, A. Neuroimaging and neurologic findings in COVID-19 and other coronavirus infections: A systematic review in 116 patients. J. Neuroradiol. 2021, 48, 43–50. [Google Scholar] [CrossRef]
  45. Zhai, Z.; Li, C.; Chen, Y.; Gerotziafas, G.; Zhang, Z.; Wan, J.; Liu, P.; Elalamy, I.; Wang, C.; On behalf of the Prevention Treatment of VTE Associated with COVID-19 Infection Consensus Statement Group; et al. Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines. Thromb. Haemost. 2020, 120, 937–948. [Google Scholar] [CrossRef]
  46. Watson, V.L.; Louis, N.; Seminara, B.V.; Muizelaar, J.P.; Alberico, A. Proposal for the rapid reversal of coagulopathy in patients with nonoperative head injuries on anticoag-ulants and/or antiplatelet agents: A case study and literature review. Neurosurgery 2017, 81, 899–909. [Google Scholar] [CrossRef]
  47. Kembuan, M.A.H.N.; Mawuntu, A.H.P.; Yohanna, Y.; Feliana, F.; Tumboimbela, M.J. Lower GCS is Related to Poor Outcome among Acute Stroke Patients with COVID-19 in A Tertiary Referral Hospital in Indonesia. Indones. Biomed. J. 2021, 13, 409–417. [Google Scholar] [CrossRef]
  48. Elgendy, S.O.; Elgendy, M.O.; El-Gendy, A.O.; Hamied, A.M.A.; Al Amir, K.; Gad, R.A.; Fahmy, A.M. Health Care Workers’ Awareness about the Post-COVID Syndrome and Different Types of COVID-19 Vaccines in Egypt. NeuroQuantology 2022, 20, 3830–3839. [Google Scholar]
Table 1. Characteristics of the studied patients and disease characteristics of COVID-19 (symptoms and CT).
Table 1. Characteristics of the studied patients and disease characteristics of COVID-19 (symptoms and CT).
CharacteristicsValues No. = 53 (%)
Age (mean ± SD)59.1 ± 14.2
Sex
Females
Males

23 (43.4%)
30  (56.6%)
Fever15 (28.3%)
Dyspnea13 (24.5%)
Diarrhea14 (26.4%)
nausea and vomiting14 (26.4%)
need to oxygen
Ordinary oxygen therapy
high flow nasal
Mechanical Ventilation

32 (60.4%)
10 (18.9%)
11 (20.8%)
CT chest
CORAD 3
CORAD 4
CORAD 5

27 (50.9%)
16 (30.2%)
10 (18.9%)
Table 2. Neurological symptoms and CT brain findings on admission.
Table 2. Neurological symptoms and CT brain findings on admission.
ItemsValues No. = 53 (%)
GCS (mean ± SD)
median(IQR)
11.5 ± 3.5
13 (8)
Headache3 (5.7%)
diminished vision1 (1.9%)
Weakness
left side
right side

19 (35.8%)
14 (26.4%)
CT findings
-basal ganglia hematoma
bilateral
left
right

-thalamic hematoma
bilateral
left
right

-temporo-parietal hematoma
bilateral
left
right

-frontal hematoma
bilateral
right

-midline shift and brain edema


3 (5.7%)
4 (7.5%)
3 (5.7%)


5 (9.4%)
3 (5.7%)
14 (26.4%)


2 (3.8%)
5 (9.4%)
1 (1.9%)


1 (1.9%)
1 (1.9%)

15 (28.3%)
IV hemorrhage13 (24.6%)
pontine hemorrhage2 (3.8%)
Hydrocephalus3 (5.7%)
hematoma size(mean ± SD)
median(IQR)
14.9 ± 11.9
9 (14)
Hematoma course on admission
stationary
regressive
progressive

15 (28.3%)
12 (22.6%)
26 (49.1%)
Table 3. Management of the studied patients regarding their COVID-19 disease and neurosurgical management.
Table 3. Management of the studied patients regarding their COVID-19 disease and neurosurgical management.
ItemsValues No. = 53 (%)
Enoxaparin
No
Prophylactic dose on day 3
Prophylactic dose on day 3 then therapeutic dose on day 7

8 (15.1%)
17 (32.1%)
28 (52.8%)
surgical management
Evacuation
VSD(ventriculo-subglia drain)

5 (9.4%)
3 (5.7%)
Table 4. The outcomes of the studied patients.
Table 4. The outcomes of the studied patients.
ItemsValues No. = 53 (%)
Chest Condition
Improved
Not improved

36 (67.9%)
17 (32.1%)
Headache
Improved
Not improved

3 (100%)
      0     0
GCS
Improved
Not improved

36 (67.9%)
17 (32.1%)
Weakness
Improved
Not improved

      0   0
     33     (100%)
Hematoma course
decreased
increased

27 (50.9%)
26 (49.1%)
Medline shift and brain edema
Improved
Not improved

36 (67.9%)
17 (32.1%)
COVID-19 symptoms
Improved
Not improved

36 (67.9%)
17 (32.1%)
Table 5. Relations between mortality and different patients’ characteristics.
Table 5. Relations between mortality and different patients’ characteristics.
CharacteristicsAlive (No. = 36)Died (No. = 17)p-Value
Age (mean ± SD)59.14 ± 13.50859.00 ± 16.1090.974
Sex
Females
Males

17 (73.9%)
19 (63.3%)

6 (26.1%)
11 (36.7%)

0.413
need to oxygen
Ordinary oxygen therapy
high flow nasal
Mechanical Ventilation

26 (81.3%)
8 (80.0%)
2 (18.2%)

6(18.8%)
2(20.0%)
9(81.8%)
CT chest
CORAD 3
CORAD 4
CORAD 5

20 (74.1%)
15 (93.8%)
1 (10.0%)

7 (25.9%)
1 (6.3%)
9 (90.0%)
GCS (mean ± SD)13.3 ± 1.77.53 ± 4.064<0.001 *
midline shift and brain edema
No
yes

32 (84.2%)
4 (26.7%)

6 (15.8%)
11 (73.3%)

<0.001 *
basal ganglia hematoma
No
bilateral
left
right

29 (67.4%)
2 (66.7%)
4 (100.0%)
1 (33.3%)

14 (32.6%)
1 (33.3%)
0 (0.0%)
2 (66.7%)

FET
0.308
thalamic hematoma
No
bilateral
left
right

19 (61.3%)
3 (60.0%)
3 (100.0%)
11 (78.6%)

12 (38.7%)
2 (40.0%)
0 (0.0%)
3 (21.4%)

FET
0.520
tempro-parietal hematoma
No
bilateral
left
right

33 (73.3%)
1 (50.0%)
1 (20.0%)
1 (100.0%)

12 (26.7%)
1 (50.0%)
4 (80.0%)
0 (0.0%)

FET
0.047 *
frontal hematoma
No
bilateral
right

34 (66.7%)
1 (100.0%)
1 (100.0%)

17 (33.3%)
0 (0.0%)
0 (0.0%)

FET
0.475
IV hemorrhage
No
Yes

26 (65%)
10 (76.9%)

14 (35%)
3 (23.1%)

FET
0.471
pontine hemorrhage
No
Yes

34 (66.7%)
2 (100.0%)

17 (33.3%)
0 (0.0%)

0.457
FET
Hydrocephalus
No
Yes

33 (66.0%)
3 (100.0%)

17 (34.0%)
0 (0.0%)

0.305
hematoma size(mean ± SD)4.61 ± 2.56713.00 ± 3.202<0.001 *
Hematoma course on admission
stationary
regressive
progressive

15 (100%)
12 (100%)
9 (34.6%)

0 (0%)
0 (0%)
17 (65.4%)

<0.001 *
<0.001 *
0.333
Enoxaparin
No
Prophylactic dose on day3
Prophylactic dose on day3 then therapeutic dose on day 7

2 (25.0%)
13 (76.5%)
21 (75.0%)

6 (75.0%)
4 (23.5%)
7 (25.0%)

0.026 *
Chest Condition
Improved
Not improved

36 (100.0%)
0 (0.0%)

0 (0.0%)
17 (100.0%)

<0.001 *
Headache
Improved
Not improved

3 (100.0%)
0 (0.0%)

0 (0.0%)
0 (0.0%)

<0.001 *
GCS
Improved
Not improved

36 (100.0%)
0 (0.0%)

0 (0.0%)
17 (100.0%)

<0.001 *
Weakness (no = 39)
Improved
Not improved

0 (0%)
30 (91%)

0 (0%)
3 (9%)

<0.001 *
Hematoma size
-Stable or decrease
-Increase

36 (100.0%)
0 (0.0%)

0 (0.0%)
17 (100.0%)

<0.001 *
Medline shift and brain edema
Improved
Not improved

36 (100.0%)
0 (0.0%)

0 (0.0%)
17 (100.0%)

<0.001 *
COVID-19 symptoms
Improved
Not improved

36 (100.0%)
0 (0.0%)

0 (0.0%)
17 (100.0%)

<0.001 *
ICU stay (days)12.28 ± 7.7007.29 ± 5.1930.019 *
(*) means significance.
Table 6. Relations between enoxaparin and the outcome of the study (presentations, mortality, and ICU stay).
Table 6. Relations between enoxaparin and the outcome of the study (presentations, mortality, and ICU stay).
ItemsNot Administered Enoxaparin (No. = 8)Administered Enoxaparin
(No. = 45)
p-Value
Chest Condition
Improved
Not improved

2 (5.6%)
6 (35.3%)

34 (94.4%)
11 (64.7%)

0.010 *
GCS
Improved
Not improved

2 (5.6%)
6 (35.3%)

34 (94.4%)
11 (64.7%)

0.010 *
Weakness
Improved
Not improved

0 (0%)
2 (6%)

0 (0%)
31 (94%)

0.850
Hematoma course
decreased
increased

2 (7.4%)
6 (23.1%)

25 (92.6%)
20 (76.9%)

0.010 *
Medline shift and brain edema
Improved
Not improved

2 (5.6%)
6 (35.3%)

34 (94.4%)
11 (64.7%)

0.010 *
COVID-19 symptoms
Improved
Not improved

2 (5.6%)
6 (35.3%)

34 (94.4%)
11 (64.7%)

0.010 *
Mortality
Alive
Died

2 (5.6%)
6 (35.3%)

34 (94.4%)
11 (64.7%)

0.010 *
ICU stay (days)2.38 ± 74412.16 ± 6.9740.019 *
(*) means significance.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Shaban, M.; Elgendy, M.O.; Fahmy, A.M.; Khalil, D.M.; El-Gendy, A.O.; Mahmoud, T.M.; Abdelrahim, M.E.A. The Outcomes of COVID-19 Patients with Spontaneous Intracerebral Hemorrhage Comorbidity and the Efficacy of Enoxaparin in Decreasing the Mortality Rate in Them: Single Egyptian Center Report. J. Pers. Med. 2022, 12, 1822. https://doi.org/10.3390/jpm12111822

AMA Style

Shaban M, Elgendy MO, Fahmy AM, Khalil DM, El-Gendy AO, Mahmoud TM, Abdelrahim MEA. The Outcomes of COVID-19 Patients with Spontaneous Intracerebral Hemorrhage Comorbidity and the Efficacy of Enoxaparin in Decreasing the Mortality Rate in Them: Single Egyptian Center Report. Journal of Personalized Medicine. 2022; 12(11):1822. https://doi.org/10.3390/jpm12111822

Chicago/Turabian Style

Shaban, Mohamed, Marwa O. Elgendy, Alzhraa M. Fahmy, Doaa Mahmoud Khalil, Ahmed O. El-Gendy, Tamer M. Mahmoud, and Mohamed E. A. Abdelrahim. 2022. "The Outcomes of COVID-19 Patients with Spontaneous Intracerebral Hemorrhage Comorbidity and the Efficacy of Enoxaparin in Decreasing the Mortality Rate in Them: Single Egyptian Center Report" Journal of Personalized Medicine 12, no. 11: 1822. https://doi.org/10.3390/jpm12111822

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop